Education
About Us
Working with TipRanks
Follow Us
Qiagen NV (QGEN)
NYSE:QGEN
Top Page
Qiagen
(NYSE:QGEN)
75Outperform
Positive Factors
Capital Allocation
Qiagen is planning its first-ever dividend and a $500 million share buyback, indicating a strong capital allocation strategy.
Financial Performance
QGEN has reaffirmed sales growth expectations and increased its earnings forecast, demonstrating strong financial performance.
Product Demand
QGEN's Diagnostic Solutions segment showed strong demand, particularly for QuantiFERON and QIAstat, indicating healthy market interest.
Negative Factors
Instrument Demand
The one blemish was cautious instrument demand, which was not surprising.
Product Discontinuation
The NeuMoDx segment is underperforming and is scheduled for discontinuation, which could impact future revenue streams.
Segment Performance
Core growth in the genomics and NGS segment declined and was below expectations, reflecting challenges in some areas.
Qiagen (QGEN) vs. S&P 500 (SPY)
Market Cap
$9.05B
Dividend YieldN/A
Average Volume (3M)1.53M
Price to Earnings (P/E)100.3
Beta (1Y)0.74
Revenue Growth3.31%
EPS GrowthN/A
CountryUS
Employees5,067
SectorHealthcare
Sector Strength46
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.55
Shares Outstanding216,116,100
10 Day Avg. Volume1,299,244
30 Day Avg. Volume1,528,472
Financial Highlights & Ratios
PEG Ratio-14.79
Price to Book (P/B)2.54
Price to Sales (P/S)0.00
P/FCF Ratio18.01
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue1.25
Enterprise Value/Gross Profit9.99
Enterprise Value/Ebitda5.76
Forecast
1Y Price Target
$48.84Price Target Upside13.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Qiagen Business Overview & Revenue Model
Company DescriptionQiagen N.V. is a leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from biological samples. Operating in the life sciences and molecular diagnostics sectors, Qiagen offers a comprehensive portfolio of products and services, including sample technologies, assay technologies, bioinformatics, and automation systems. These products are utilized in academic research, pharmaceutical and biotechnology industries, forensics, and clinical diagnostics to advance scientific research and improve patient outcomes.
How the Company Makes MoneyQiagen generates revenue through the sale of its diverse range of products and services designed to automate and streamline the process of extracting, analyzing, and interpreting molecular information. Its key revenue streams include: 1) Consumables and related products, comprising kits and reagents used in sample preparation and molecular testing. 2) Instruments, which include automation systems for sample processing and analysis. 3) Bioinformatics solutions, providing software and services for data interpretation and analysis. Additionally, Qiagen benefits from strategic partnerships and collaborations with academic institutions, pharmaceutical companies, and clinical laboratories, which enhance its market reach and drive sales growth. The company's focus on innovation and expanding its product offerings in high-demand areas, such as oncology and infectious disease testing, also significantly contributes to its earnings.
Qiagen Financial Statement Overview
Summary
Qiagen exhibits a solid financial foundation with strong cash flow and balance sheet metrics. Revenue and profitability have seen some decline, but the company maintains efficiency and leverage stability. Continued focus on increasing profitability could enhance financial performance further.Income Statement
Qiagen's revenue has shown fluctuations over the years, with a notable decline from 2021 to 2024. The gross profit margin remains relatively strong, indicating efficient cost management. However, the net profit margin has decreased significantly due to a fall in net income, suggesting challenges in maintaining profitability.72
Positive
Balance Sheet
The company's balance sheet is relatively strong, with a solid equity position. The debt-to-equity ratio has improved, indicating a stable leverage situation. However, the return on equity has decreased, reflecting reduced profitability relative to shareholder investments.75
Positive
Cash Flow
Qiagen has demonstrated strong cash flow management, with consistent free cash flow generation. The operating cash flow to net income ratio is healthy, suggesting effective conversion of income to cash. There is substantial growth in free cash flow, despite fluctuations in net income.80
Positive
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 1.98B | 1.97B | 2.14B | 2.25B | 1.87B | Gross Profit |
| 1.32B | 1.22B | 1.38B | 1.45B | 1.23B | EBIT |
| 97.71M | 445.25M | 531.46M | 630.08M | 554.90M | EBITDA |
| 368.26M | 688.55M | 779.36M | 895.24M | 715.80M | Net Income Common Stockholders |
| 83.59M | 341.30M | 423.21M | 512.60M | 73.64M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.15B | 1.06B | 1.42B | 1.07B | 714.25M | Total Assets |
| 5.69B | 6.12B | 6.29B | 6.15B | 5.97B | Total Debt |
| 1.42B | 1.61B | 1.86B | 1.94B | 2.03B | Net Debt |
| 752.33M | 943.04M | 1.13B | 1.06B | 1.43B | Total Liabilities |
| 2.12B | 2.31B | 2.82B | 3.05B | 3.49B | Stockholders Equity |
| 3.57B | 3.81B | 3.47B | 3.10B | 2.48B |
| Cash Flow | Free Cash Flow | |||
| 506.38M | 296.65M | 565.93M | 432.47M | 188.03M | Operating Cash Flow |
| 673.55M | 459.45M | 715.26M | 639.00M | 492.27M | Investing Cash Flow |
| -249.23M | -87.66M | -726.76M | -202.43M | -453.29M | Financing Cash Flow |
| -422.90M | -433.83M | -125.80M | -150.37M | -74.32M |
Qiagen Technical Analysis
Positive
42.96
Price Trends
40.64
Positive
41.99
Positive
43.13
Negative
Market Momentum
0.50
Positive
56.83
Neutral
29.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QGEN, the sentiment is Positive. The current price of 42.96 is above the 20-day moving average (MA) of 42.20, above the 50-day MA of 40.64, and below the 200-day MA of 43.13, indicating a neutral trend. The MACD of 0.50 indicates Positive momentum. The RSI at 56.83 is Neutral, neither overbought nor oversold. The STOCH value of 29.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QGEN.
Qiagen Risk Analysis
Qiagen disclosed 38 risk factors in its most recent earnings report. Qiagen reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Qiagen Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $19.76B | 22.37 | 13.35% | 1.72% | 9.38% | 6.43% | |
75 Outperform | $9.05B | 100.29 | 2.67% | ― | 3.31% | ― | |
73 Outperform | $20.60B | ― | -18.66% | ― | 51.50% | 53.23% | |
65 Neutral | $10.76B | 36.08 | 3.82% | 0.31% | 1.62% | 78.53% | |
61 Neutral | $9.74B | ― | -36.89% | ― | 11.57% | -315.25% | |
55 Neutral | $11.99B | ― | -23.82% | ― | -3.47% | 25.55% | |
52 Neutral | $5.15B | 3.56 | -42.52% | 2.83% | 14.56% | -0.50% |
* Healthcare Sector Average
Performance Comparison
QGEN
Qiagen
42.96
-1.36
-3.07%
EXAS
Exact Sciences
51.63
-3.96
-7.12%
ILMN
Illumina
75.76
-33.83
-30.87%
RVTY
Revvity
98.50
-6.78
-6.44%
DGX
Quest Diagnostics
176.96
38.98
28.25%
NTRA
Natera
151.95
48.62
47.05%
Qiagen Earnings Call Summary
Earnings Call Date:May 07, 2025
(Q1-2025)
| % Change Since: 0.77%|
Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment Positive
Qiagen delivered a strong start to 2025, exceeding expectations for net sales and earnings. Key product lines showed robust growth, and profitability improved significantly. While challenges remain in the China market and cautious customer spending, the company reaffirmed its full-year outlook and expanded shareholder return options, indicating confidence in its strategy and execution.Q1-2025 Updates
Positive Updates
Exceeded Q1 2025 Outlook
Qiagen delivered net sales of $483 million, representing a 7% increase at constant exchange rates (CER) compared to Q1 2024. Adjusted diluted earnings per share were $0.50, exceeding the outlook for at least $0.50.
Strong Performance of Key Products
QIAstat achieved double-digit sales growth, QuantiFERON tuberculosis test delivered another strong quarter of double-digit sales growth, and QIAcuity digital PCR platform continued to build momentum in high-growth fields.
Increased Profitability
Adjusted operating income margin rose to 29.8% of sales, up more than four percentage points from Q1 2024, driven by a favorable shift towards consumables and bioinformatics solutions.
Reaffirmed Full Year 2025 Outlook
Qiagen expects around 4% sales growth at CER, with an upgraded target for adjusted earnings per share of about $2.35, up $0.07 from the initial outlook for the year.
Expansion of Shareholder Returns
Introduction of an annual cash dividend and proposal for a synthetic share repurchase of up to $500 million for consideration over an 18-month period.
Negative Updates
Challenges in China
Ongoing weak trends in China, which represents about 3% to 4% of total sales, with a high teens CER decline compared to Q1 2024.
Decline in Genomics and NGS Sales
Sales in genomics and next-generation sequencing were down 2% at CER compared to Q1 2024, reflecting lower demand for some NGS consumables and services.
Cautious Customer Spending
Continued cautious environment on spending, especially for capital sales, and discussions around research funding in different countries.
Company Guidance
In the Q1 2025 earnings call, Qiagen reported exceeding their outlook with net sales of $483 million, reflecting a 7% increase at constant exchange rates (CER) compared to Q1 2024. Adjusted diluted earnings per share were $0.50 at CER, surpassing the expected minimum of $0.50. The company reaffirmed its full-year 2025 outlook, projecting around 4% sales growth at CER, and upgraded its adjusted earnings per share target to approximately $2.35 at CER, up $0.07 from the initial guidance. Key growth drivers included QIAstat's double-digit sales increase due to new panel launches, QuantiFERON's strong performance with double-digit sales growth, and the momentum in QIAcuity's digital PCR platform. Qiagen also highlighted its strategic initiatives, including the introduction of a cash dividend and a proposed $500 million synthetic share repurchase, as part of its goal to return at least $1 billion to shareholders by 2028.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.